Advertisement
Advertisement
TOPIC

Biomedicine: Science

Related Topics:
Biomedicine: Science
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
The US$60 billion deal value represents a 73 per cent jump from the same period a year earlier. Photo: Shutterstock
Biomedicine: Companies

China biotech deals hit record as innovative drugs draw global interest

Deals reach US$60 billion in first quarter after analysts say Chinese biotech firms have shown substantial technological advancements.

Biomedicine: Companies

In a first for China, Neuracle’s brain-computer interface wins approval

Science

Chinese gene-editing technique raises prospect of new autism treatments

videocam
US-China relations

Opinion | China has Trump 2.0 to thank for emerging stronger in tech and trade

As intense US-China competition becomes the new normal, pressure has strengthened China’s capacity to adapt rather than deter it from its long-term ambitions.

videocam
President Xi Jinping attends a high-level reception to ring in the Lunar New Year at the Great Hall of the People in Beijing, on January 27, 2025. Photo: Xinhua
Science

Structural biologist Alexey Amunts launches new research lab in Shenzhen

‘Shenzhen adds another dimension; it is a place where ideas do not remain ideas for long,’ Amunts says of new position.

videocam
8
Made in China 2025

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Advertisement
Advertisement
Advertisement
Insilico

Insilico signs US$888 million AI drug deal days after Hong Kong IPO

Multi-year partnership with France’s Servier will use Insilico’s AI platform to explore novel cancer drugs.

The deal further validates Insilico’s AI-driven drug discovery platform, which the company claims can slash drug-development timelines to 12 to 18 months from the average of 4.5 years. Photo: Shutterstock
Science

China’s biopharma sector ‘in prime position to challenge US leadership’

American commission issues stark warning, as analytics firm Clarivate reports that Chinese innovative drug development has entered new phase.

videocam
33
IPO

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.

Made in China 2025

China’s rising biotech clout on show in flurry of billion-dollar licensing deals

A burst of overseas licensing pacts is spotlighting China’s biotech sector, as Jacobio, Coherent Biopharma and Harbour BioMed land deals.

The latest transactions reflect a broader pattern of multinational drugmakers turning to Chinese biotechs for pipeline replenishment. Photo: Shutterstock
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong
Science

How Chinese scientists turn allergy into a powerful weapon against cancer

Mast cell platform can expand to carry other payloads, such as molecules, viruses, proteins and drug-loaded nanoparticles.

videocam
Made in China 2025

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

A number of Chinese biotech firms have clinched licensing deals with multinational companies this year. Photo: Shutterstock
Science

Sperm quality decline: could easy-to-use balm from China solve the crisis?

In China, unhealthy lifestyles, pollution and work-related stress are cited in public health discussions around declining sperm quality.

videocam
A national reproductive health survey in 2021 indicated one in nearly six couples of childbearing age faced difficulties in starting a family. Photo: Getty Images
Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
Advertisement
Advertisement
Advertisement
Hong Kong stock market

China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline

Share placement to help Shenyang-based firm advance clinical research in China and the US, expand reach of cancer and hair-loss drugs.

Shenyang-based 3SBio is selling a 4.14 per cent stake in the company. Photo: Handout
Biomedicine: Industry Trends

China’s clinical trial capacity matches US, attracts more global pharma firms

Growth of innovative clinical trials suggests that Chinese biotech firms’ pipeline of novel drug candidates is expanding, analysts say.

New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Hong Kong healthcare and hospitals

Hong Kong biotech firm to back controversial sanitary pad HPV test with evidence

Dr Choi Pui-wah, founder of WomenX Biotech, also says she remains optimistic about Hong Kong as a tech destination despite government warning.

Dr Choi Pui-wah, founder of WomenX Biotech, also says she remains optimistic about Hong Kong as a tech destination. Photo: K. Y. Cheng
Biomedicine: Companies

China biotech forum bills antibody cancer drugs as next-generation treatment

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies.

Antibody drug conjugates are targeted medicines that deliver chemotherapy agents to cancer cells. Photo: Shutterstock
Hong Kong stock market

China’s Akeso gets share boost as data shows cancer drug’s benefits

Lung-cancer drug ivonescimab is ‘potentially two to three years ahead of competitors’, analyst says.

Biomedicine: Companies

Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals

Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.

Biomedicine: Companies

Hong Kong MRI maker Time Medical seeks site to boost output, eyes IPO

Aiming to grow sales to US$300 million in 2027, the company is eyeing a Nasdaq IPO and then a Hong Kong secondary listing.

Ma Qiyuan, Time Medical Systems co-founder and chairman, pictured with one of the company’s scanners in its facility in Tai Po on October 6, 2025. Photo: Jonathan Wong
Biomedicine: Companies

Mirxes wins China’s approval to launch groundbreaking gastric cancer blood test

The non-invasive blood test helps in the early detection of the fifth leading cause of cancer deaths globally.

GastroClear, the first microRNA blood test approved in China for the early detection of gastric cancer, evaluates risks by detecting 12 miRNA biomarkers, according to developer Mirxes. Photo: Handout
Health & Fitness

Li Ka-shing-backed focused ultrasound therapy treats 1 millionth case

The therapy, which uses ultrasound energy to treat a number of diseases including cancer, is gaining global traction, a US expert says.

US-China relations

Opinion | Why US-China health and drugs cooperation must top Trump-Xi agenda

The years-long impasse harms both nations and the world, and the stakes in global health security could not be higher.

videocam
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement